Nanoparticle Technologies: Enablers for Ocular Drug Delivery

[Article Title]

As we continue to discover new and innovative small molecules and therapeutic compounds, over 80% of those candidates in drug pipeline are challenging to development due to their poor solubility and bioavailability. There are several ocular barriers such as tear film, corneal, conjunctival and blood barriers that cause the bioavailability issues. A nanotechnology-based drug delivery system (NODS) remains the acceptable and eff ective ways for ocular administration of drugs. This article will describe the basic understanding of challenges in ocular drug delivery and the future trends in development of innovative drugs.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.